Last reviewed · How we verify

Klebsiella Joint Infection — Treatment Landscape & Competitive Intelligence

Klebsiella Joint Infection (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Klebsiella Joint Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Fortaz CEFTAZIDIME Pai Holdings Pharm ceftazidime 1985-01-01
Rocephin ceftriaxone Generic (originally Roche) Cephalosporin antibiotic (third-generation) Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A 1984-12-21
Ceftriaxon Ceftriaxon Centre Hospitalier Universitaire Vaudois Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Ceftazidim Ceftazidim Tel-Aviv Sourasky Medical Center Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pai Holdings Pharm · 2 drugs in Klebsiella Joint Infection
  2. Centre Hospitalier Universitaire Vaudois · 1 drug in Klebsiella Joint Infection
  3. Generic (originally Roche) · 1 drug in Klebsiella Joint Infection
  4. Tel-Aviv Sourasky Medical Center · 1 drug in Klebsiella Joint Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Klebsiella Joint Infection:

Cite this brief

Drug Landscape (2026). Klebsiella Joint Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/klebsiella-joint-infection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing